Regeneron Pharmaceuticals Inc. buy TD Cowen
Summary
This prediction is currently active. The prediction currently has a performance of 17.18%. This prediction currently runs until 06.12.24. The prediction end date can be changed by TD_Cowen at any time. TD_Cowen has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Regeneron Pharmaceuticals Inc. | 0.593% | 0.593% |
iShares Core DAX® | -0.268% | 5.471% |
iShares Nasdaq 100 | 1.854% | 7.851% |
iShares Nikkei 225® | 0.284% | 1.729% |
iShares S&P 500 | 1.178% | 5.269% |
Comments by TD_Cowen for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Stopped prediction by TD_Cowen for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
24.04.24
24.04.25
18:55